ASH 2020 | The phase III trial Apollo supports administering daratumumab subcutaneously instead of intravenously in relapsed or refractory myeloma patientsConferences, Myeloma5 December 2020
ASH 2020 | Visit our poster on myeloma patient information needs and preferences at ASH 2020!Conferences, MPE, Myeloma5 December 2020
Register now for MPE’s webinar on Evidence-Based Patient AdvocacyMPE, Patient evidence19 October 2020
ASCO and EHA highlights in myeloma and AL amyloidosisAL amyloidosis, Conferences, MPE, Myeloma, Videos20 July 2020
